The contribution of
nociceptin/orphanin FQ (N/OFQ) to
reserpine-induced
Parkinsonism was evaluated in mice. A battery of motor tests revealed that
reserpine caused dose-dependent and long-lasting motor impairment. Endogenous N/OFQ sustained this response because
N/OFQ peptide (NOP) receptor knockout (NOP(-/-) ) mice were less susceptible to the hypokinetic action of
reserpine than wild-type (NOP(+/+) ) animals. Microdialysis revealed that
reserpine elevated
glutamate and reduced
GABA levels in substantia nigra reticulata, and that resistance to
reserpine in NOP(-/-) mice was accompanied by a milder increase in
glutamate and lack of inhibition of
GABA levels. To substantiate this genetic evidence, the NOP receptor antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H
benzimidazol-2-one (J-113397) simultaneously reduced akinesia and nigral
glutamate levels in reserpinized NOP(+/+) mice, being ineffective in NOP(-/-) mice. Moreover, repeated
J-113397 administration in reserpinized mice resulted in faster recovery of baseline motor performance which was, however, accompanied by a loss of acute antiakinetic response. The short-term beneficial effect of
J-113397 was paralleled by normalization of nigral
glutamate levels, whereas loss of acute response was paralleled by loss of the ability of
J-113397 to inhibit
glutamate levels. We conclude that endogenous N/OFQ contributes to
reserpine-induced
Parkinsonism, and that sustained NOP receptor blockade produces short-term motor improvement accompanied by normalization of nigral
glutamate release.